OptiBiotix Health Plc

LSE:OPTI UK Biotechnology
Market Cap
$80.44K
GBX661.12 Million GBX
Market Cap Rank
#48511 Global
#1198 in UK
Share Price
GBX6.40
Change (1 day)
+8.47%
52-Week Range
GBX5.75 - GBX20.50
All Time High
GBX128.00
Categories
Companies in UK Biotechnology
About

OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential… Read more

OptiBiotix Health Plc (OPTI) - Net Assets

Latest net assets as of June 2025: GBX8.42 Million GBX

Based on the latest financial reports, OptiBiotix Health Plc (OPTI) has net assets worth GBX8.42 Million GBX as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX9.15 Million) and total liabilities (GBX732.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets GBX8.42 Million
% of Total Assets 92.0%
Annual Growth Rate 15.18%
5-Year Change -29.14%
10-Year Change 120.03%
Growth Volatility 976.48

OptiBiotix Health Plc - Net Assets Trend (2008–2024)

This chart illustrates how OptiBiotix Health Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for OptiBiotix Health Plc (2008–2024)

The table below shows the annual net assets of OptiBiotix Health Plc from 2008 to 2024.

Year Net Assets Change
2024-12-31 GBX8.40 Million -5.34%
2023-12-31 GBX8.87 Million -18.64%
2022-12-31 GBX10.90 Million -39.99%
2021-12-31 GBX18.17 Million +53.34%
2020-12-31 GBX11.85 Million +137.91%
2019-12-31 GBX4.98 Million -29.47%
2018-11-30 GBX7.06 Million +0.24%
2017-11-30 GBX7.05 Million +40.83%
2016-11-30 GBX5.00 Million +31.08%
2015-11-30 GBX3.82 Million -17.90%
2014-11-30 GBX4.65 Million +3911.91%
2013-11-30 GBX115.88K -73.68%
2012-07-31 GBX440.35K -43.03%
2010-07-31 GBX773.00K -4.57%
2009-07-31 GBX810.00K -1.82%
2008-07-31 GBX825.00K --

Equity Component Analysis

This analysis shows how different components contribute to OptiBiotix Health Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 67200000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings GBX585.00K 6.97%
Common Stock GBX1.96 Million 23.33%
Other Comprehensive Income GBX1.75 Million 20.80%
Other Components GBX4.11 Million 48.90%
Total Equity GBX8.40 Million 100.00%

OptiBiotix Health Plc Competitors by Market Cap

The table below lists competitors of OptiBiotix Health Plc ranked by their market capitalization.

Company Market Cap
Amana Takaful PLC
CM:ATLN0000
 		$722.87
FANCAMP EXPLORATION
BE:3F9
 		$724.02
Burshane LPG (Pakistan) Ltd
KAR:BPL
 		$725.27
Allied Healthcare Products Inc.
PINK:AHPIQ
 		$726.24
Panther Metals PLC
LSE:PALM
 		$722.29
Modern Company For Water Proofing (Bitumode)
EGX:WATP
 		$721.37
4Global PLC
LSE:4GBL
 		$721.22
Healthwarehouse.Com
OTCQB:HEWA
 		$720.96

Equity Growth Attribution

This analysis shows how different factors contributed to changes in OptiBiotix Health Plc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 8,872,000 to 8,398,000, a change of -474,000 (-5.3%).
  • Net loss of 1,805,000 reduced equity.
  • New share issuances of 1,285,000 increased equity.
  • Other comprehensive income decreased equity by 525,000.
  • Other factors increased equity by 571,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income GBX-1.80 Million -21.49%
Share Issuances GBX1.28 Million +15.3%
Other Comprehensive Income GBX-525.00K -6.25%
Other Changes GBX571.00K +6.8%
Total Change GBX- -5.34%

Book Value vs Market Value Analysis

This analysis compares OptiBiotix Health Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 74.61x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 0.06x to 74.61x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2008-07-31 GBX103.84 GBX6.40 x
2009-07-31 GBX101.95 GBX6.40 x
2010-07-31 GBX97.29 GBX6.40 x
2012-07-31 GBX2.41 GBX6.40 x
2013-11-30 GBX0.16 GBX6.40 x
2014-11-30 GBX0.17 GBX6.40 x
2015-11-30 GBX0.05 GBX6.40 x
2016-11-30 GBX0.06 GBX6.40 x
2017-11-30 GBX0.08 GBX6.40 x
2018-11-30 GBX0.09 GBX6.40 x
2019-12-31 GBX0.06 GBX6.40 x
2020-12-31 GBX0.12 GBX6.40 x
2021-12-31 GBX0.19 GBX6.40 x
2022-12-31 GBX0.12 GBX6.40 x
2023-12-31 GBX0.10 GBX6.40 x
2024-12-31 GBX0.09 GBX6.40 x

Capital Efficiency Dashboard

This dashboard shows how efficiently OptiBiotix Health Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -21.49%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -207.47%
  • • Asset Turnover: 0.10x
  • • Equity Multiplier: 1.08x
  • Recent ROE (-21.49%) is above the historical average (-134.34%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2008 -3.88% 0.00% 0.00x 1.06x GBX-114.50K
2009 -1.98% 0.00% 0.00x 1.01x GBX-97.00K
2010 -4.66% 0.00% 0.00x 1.01x GBX-113.30K
2012 -375.38% -1022.92% 0.19x 1.91x GBX-1.70 Million
2013 -1700.85% 0.00% 0.00x 3.14x GBX-1.64 Million
2014 -17.44% 0.00% 0.00x 1.11x GBX-1.28 Million
2015 -33.56% -4542.55% 0.01x 1.15x GBX-1.66 Million
2016 -26.42% -450.51% 0.05x 1.15x GBX-1.79 Million
2017 27.11% 998.05% 0.02x 1.09x GBX1.20 Million
2018 -27.31% -373.14% 0.06x 1.14x GBX-2.62 Million
2019 -47.88% -317.90% 0.11x 1.37x GBX-2.86 Million
2020 49.11% 380.96% 0.11x 1.16x GBX4.62 Million
2021 34.52% 282.92% 0.11x 1.11x GBX4.45 Million
2022 23.72% 566.08% 0.04x 1.06x GBX1.50 Million
2023 -22.98% -316.61% 0.07x 1.06x GBX-2.93 Million
2024 -21.49% -207.47% 0.10x 1.08x GBX-2.64 Million

Industry Comparison

This section compares OptiBiotix Health Plc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $10,807,025
  • Average return on equity (ROE) among peers: -134.93%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
OptiBiotix Health Plc (OPTI) GBX8.42 Million -3.88% 0.09x $722.70
4BASEBIO UK SOCIETAS (4BB) $11.70 Million -27.66% 0.26x $10.53K
Aptamer Group PLC (APTA) $8.05 Million -26.00% 0.43x $3.12K
Arecor Therapeutics PLC (AREC) $773.79K -355.70% 4.54x $3.33K
Bioventix (BVXP) $4.20 Million 36.18% 0.07x $9.85K
Cizzle Biotechnology Holdings PLC (CIZ) $741.00K -0.02% 3.16x $747.56
Fusion Antibodies PLC (FAB) $1.46 Million 79.21% 0.28x $2.07K
Faron Pharmaceuticals Oy (FARN) $1.61 Million -823.73% 5.34x $27.00K
Futura Medical (FUM) $9.72 Million -50.98% 0.21x $424.60
hVIVO plc (HVO) $2.86 Million -195.31% 2.17x $5.18K
International Biotechnology Trust plc (IBT) $66.95 Million 14.71% 0.00x $1.10K